<?xml version='1.0' encoding='utf-8'?>
<document id="26582036"><sentence text="The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4."><entity charOffset="29-38" id="DDI-PubMed.26582036.s1.e0" text="sorafenib" /></sentence><sentence text="1" /><sentence text=" The aim of this study was to investigate the potential drug-drug interaction of sorafenib mediated by P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4)"><entity charOffset="81-90" id="DDI-PubMed.26582036.s3.e0" text="sorafenib" /></sentence><sentence text=" 2" /><sentence text=" In this research, a sensitive and reliable LC-MS/MS method was developed and applied for the determination of sorafenib in rat plasma"><entity charOffset="111-120" id="DDI-PubMed.26582036.s5.e0" text="sorafenib" /></sentence><sentence text=" The pharmacokinetic profiles of orally administered sorafenib from rats with and without verapamil pretreatment were investigated"><entity charOffset="53-62" id="DDI-PubMed.26582036.s6.e0" text="sorafenib" /><entity charOffset="90-99" id="DDI-PubMed.26582036.s6.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26582036.s6.e0" e2="DDI-PubMed.26582036.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s6.e0" e2="DDI-PubMed.26582036.s6.e1" /></sentence><sentence text=" 3" /><sentence text=" The results indicated that when the rats were pretreated with verapamil, the Cmax of sorafenib increased from 55"><entity charOffset="63-72" id="DDI-PubMed.26582036.s8.e0" text="verapamil" /><entity charOffset="86-95" id="DDI-PubMed.26582036.s8.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.26582036.s8.e0" e2="DDI-PubMed.26582036.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s8.e0" e2="DDI-PubMed.26582036.s8.e1" /></sentence><sentence text="73 ng/ml to 87" /><sentence text="72 ng/ml (57" /><sentence text="40%), and the AUC(0-t) increased by approximately 58" /><sentence text="2% when sorafenib was co-administered with verapamil"><entity charOffset="8-17" id="DDI-PubMed.26582036.s12.e0" text="sorafenib" /><entity charOffset="43-52" id="DDI-PubMed.26582036.s12.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26582036.s12.e0" e2="DDI-PubMed.26582036.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s12.e0" e2="DDI-PubMed.26582036.s12.e1" /></sentence><sentence text=" Additionally, the effects of verapamil on the absorption of sorafenib were investigated using the Caco-2 cell transwell model, and the effects of verapamil on the metabolic stability of sorafenib were also studied using rat liver microsomes incubation systems"><entity charOffset="30-39" id="DDI-PubMed.26582036.s13.e0" text="verapamil" /><entity charOffset="61-70" id="DDI-PubMed.26582036.s13.e1" text="sorafenib" /><entity charOffset="147-156" id="DDI-PubMed.26582036.s13.e2" text="verapamil" /><entity charOffset="187-196" id="DDI-PubMed.26582036.s13.e3" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e0" e2="DDI-PubMed.26582036.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e0" e2="DDI-PubMed.26582036.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e0" e2="DDI-PubMed.26582036.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e0" e2="DDI-PubMed.26582036.s13.e3" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e1" e2="DDI-PubMed.26582036.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e1" e2="DDI-PubMed.26582036.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e1" e2="DDI-PubMed.26582036.s13.e3" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e2" e2="DDI-PubMed.26582036.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s13.e2" e2="DDI-PubMed.26582036.s13.e3" /></sentence><sentence text=" A markedly higher transport of sorafenib across the Caco-2 cells was observed in the basolateral-to-apical direction and was abrogated in the presence of the P-gp inhibitor, verapamil"><entity charOffset="32-41" id="DDI-PubMed.26582036.s14.e0" text="sorafenib" /><entity charOffset="175-184" id="DDI-PubMed.26582036.s14.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26582036.s14.e0" e2="DDI-PubMed.26582036.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s14.e0" e2="DDI-PubMed.26582036.s14.e1" /></sentence><sentence text=" The results indicated that P-gp was involved in the transport of sorafenib, and verapamil could increase its absorption in the Caco-2 cell model, and the metabolic stability of sorafenib was prolonged by the pretreatment with verapamil"><entity charOffset="66-75" id="DDI-PubMed.26582036.s15.e0" text="sorafenib" /><entity charOffset="81-90" id="DDI-PubMed.26582036.s15.e1" text="verapamil" /><entity charOffset="178-187" id="DDI-PubMed.26582036.s15.e2" text="sorafenib" /><entity charOffset="227-236" id="DDI-PubMed.26582036.s15.e3" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e0" e2="DDI-PubMed.26582036.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e0" e2="DDI-PubMed.26582036.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e0" e2="DDI-PubMed.26582036.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e0" e2="DDI-PubMed.26582036.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e1" e2="DDI-PubMed.26582036.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e1" e2="DDI-PubMed.26582036.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e1" e2="DDI-PubMed.26582036.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e2" e2="DDI-PubMed.26582036.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26582036.s15.e2" e2="DDI-PubMed.26582036.s15.e3" /></sentence><sentence text=" 4" /><sentence text=" In conclusion, the drug-drug interaction of sorafenib might happen when sorafenib was co-administered with P-gp or CYP3A4 inhibitors"><entity charOffset="45-54" id="DDI-PubMed.26582036.s17.e0" text="sorafenib" /><entity charOffset="73-82" id="DDI-PubMed.26582036.s17.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.26582036.s17.e0" e2="DDI-PubMed.26582036.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26582036.s17.e0" e2="DDI-PubMed.26582036.s17.e1" /></sentence><sentence text="" /></document>